Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation

Major Program(s) or Research Group(s)

  • Community Oncology and Prevention Trials
  • Supportive Care and Symptom Management

Sponsor

Masonic Cancer Center, University of Minnesota

Status

Recruiting

ClinicalTrials.gov ID

For more information, see ClinicalTrials.gov NCT02074631

This is a Phase 2, open-label, randomized, controlled clinical study of pediatric subjects treated with pamidronate with calcium and vitamin D versus calcium and vitamin D alone following hematopoietic cell transplantation (HCT). The purpose of this study is to test the hypothesis that subjects receiving pamidronate with calcium and vitamin D will have higher lumbar spine bone mineral content (LBMC) measured by dual-energy X-ray tomography (DXA) at 1 year post-HCT than subjects receiving calcium and vitamin D alone (Control Group).

Intervention

Pamidronate, Calcium and vitamin D

Condition

Osteopenia, Osteoporosis

Investigators

Kyriakie Sarafoglou, MD, Scott Baker, M.D., Kyriakie Sarafoglou, M.D.

See list of participating sites